Cargando…

Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment

Hypomethylating agents (HMAs) are widely used in patients with higher-risk MDS not eligible for stem cell transplantation. However, the general response rate by HMAs is lesser than 50% in MDS patients, while the relapse rate is high. Emerging evidence indicates that demethylating effects committed b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geng, Suxia, Xu, Ruohao, Huang, Xin, Li, Minming, Deng, Chengxin, Lai, Peilong, Wang, Yulian, Wu, Ping, Chen, Xiaomei, Weng, Jianyu, Du, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393298/ https://www.ncbi.nlm.nih.gov/pubmed/36003379 http://dx.doi.org/10.3389/fimmu.2022.950134

Ejemplares similares

Decitabine With or Without Micro-Transplantation for the Treatment of Intermediate or High-Risk Myelodysplastic Syndrome: A Chinese Single-Center Retrospective Study of 22 Patients
por: Li, MinMing, et al.
Publicado: (2021)

Mesenchymal stem cells reversibly de-differentiate myofibroblasts to fibroblast-like cells by inhibiting the TGF-β-SMAD2/3 pathway
por: Xu, Ruohao, et al.
Publicado: (2023)

C-Type Lectin-Like Molecule-1 as a Biomarker for Diagnosis and Prognosis in Acute Myeloid Leukemia: A Preliminary Study
por: Wang, Jinghua, et al.
Publicado: (2021)

The Gut Bacteria Dysbiosis Contributes to Chronic Graft-Versus-Host Disease Associated With a Treg/Th1 Ratio Imbalance
por: Wang, Yulian, et al.
Publicado: (2022)

Identification and Validation of a Prognostic Risk-Scoring Model Based on Ferroptosis-Associated Cluster in Acute Myeloid Leukemia
por: Wang, Jinghua, et al.
Publicado: (2022)

Lower BCL11B expression is associated with adverse clinical outcome for patients with myelodysplastic syndrome
por: Huang, Xin, et al.
Publicado: (2021)

C3aR costimulation enhances the antitumor efficacy of CAR-T cell therapy through Th17 expansion and memory T cell induction
por: Lai, Peilong, et al.
Publicado: (2022)

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
por: Yang, Hui, et al.
Publicado: (2013)

Analysis of the expression of PHTF1 and related genes in acute lymphoblastic leukemia
por: Huang, Xin, et al.
Publicado: (2015)

Deep learning-based transcriptome model predicts survival of T-cell acute lymphoblastic leukemia
por: Zhang, Lenghe, et al.
Publicado: (2022)

Attenuation of cGVHD by C5a/C5aR blockade is associated with increased frequency of Treg
por: Wang, Yulian, et al.
Publicado: (2017)

Curse and blessing: upregulation of oncogenes upon treatment with hypomethylating agents in myelodysplastic syndrome
por: Grimm, Juliane, et al.
Publicado: (2022)

A potent immunomodulatory role of exosomes derived from mesenchymal stromal cells in preventing cGVHD
por: Lai, Peilong, et al.
Publicado: (2018)

A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia
por: Weng, Jianyu, et al.
Publicado: (2018)

Correction to: A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia
por: Weng, Jianyu, et al.
Publicado: (2019)

Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents
por: Lee, Sangmin, et al.
Publicado: (2022)

Phenotype of mesenchymal stem cells from patients with myelodyplastic syndrome maybe partly modulated by decitabine
por: Pang, Yanbin, et al.
Publicado: (2019)

Novel insights into MSC-EVs therapy for immune diseases
por: Lai, Peilong, et al.
Publicado: (2019)

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
por: Liapis, Konstantinos, et al.
Publicado: (2021)

Management of myelodysplastic syndromes after failure of response to hypomethylating agents
por: Gil-Perez, Angela, et al.
Publicado: (2019)

Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome
por: Jung, Seung-Hyun, et al.
Publicado: (2016)

Oral Hypomethylating Agents for Myelodysplastic Syndromes: Highlights From SOHO 2020
Publicado: (2021)

A machine learning model of response to hypomethylating agents in myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2022)

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2018)

Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies
por: Stomper, Julia, et al.
Publicado: (2021)

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
por: Takahashi, Koichi, et al.
Publicado: (2016)

No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome
por: Sohn, Sang Kyun, et al.
Publicado: (2018)

Arsenic Disulfide Promoted Hypomethylation by Increasing DNA Methyltransferases Expression in Myelodysplastic Syndrome
por: Zhou, Qing-Bing, et al.
Publicado: (2020)

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Wong, Kah Keng, et al.
Publicado: (2021)

Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
por: Sorrentino, Vincent G., et al.
Publicado: (2021)

Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes
por: Abbas, Hussein A., et al.
Publicado: (2021)

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
por: Komrokji, Rami S., et al.
Publicado: (2022)

Senescent Mesenchymal Stem Cells in Myelodysplastic Syndrome: Functional Alterations, Molecular Mechanisms, and Therapeutic Strategies
por: Chen, Xiaofang, et al.
Publicado: (2021)

Synergistic Interactions between the Hypomethylating Agent Thio-Deoxycytidine and Venetoclax in Myelodysplastic Syndrome Cells
por: Hu, Xiaoyan, et al.
Publicado: (2023)

Comparison of Hypomethylator Monotherapy with Hypomethylator plus Chemotherapy for Intermediate/High-Risk MDS or AML: A Meta-Analysis
por: Ji, Jiang, et al.
Publicado: (2020)

PB1900: COMBINED TREATMENT WITH VENETOCLAX PLUS HYPOMETHYLATING AGENT OR CYTARABINE VERSUS TREATMENT WITH HYPOMETHYLATING AGENT ALONE IN ACUTE MYELOID LEUKEMIA IN POOR PROGNOSIS PATIENTS.
por: Saavedra, Minerva Montalvo, et al.
Publicado: (2023)

Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: A systematic review and meta-analysis
por: Gao, Chong, et al.
Publicado: (2018)

Genome-wide analysis toward the epigenetic aetiology of myelodysplastic syndrome disease progression and pharmacoepigenomic basis of hypomethylating agents drug treatment response
por: Siamoglou, Stavroula, et al.
Publicado: (2023)

Serum microRNA-21 as a Potential Biomarker for Response to Hypomethylating Agents in Myelodysplastic Syndromes
por: Kim, Yundeok, et al.
Publicado: (2014)

Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence
por: Nazha, Aziz, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i4uimnpqt79r94parf6nqo9dkr